OBJECTIVE:Caffeine is a central stimulant that increases the release of catecholamines. As a component of popular beverages, caffeine is widely used around the world. Its pharmacological effects are predominantly due to adenosine receptor antagonism and include release of catecholamines. We hypothesized that caffeine reduces insulin sensitivity, either due to catecholamines and/or as a result of blocking adenosine-mediated stimulation of peripheral glucose uptake. RESEARCH DESIGN AND METHODS: Hyperinsulinemic-euglycemic glucose clamps were used to assess insulin sensitivity. Caffeine or placebo was administered intravenously to 12 healthy volunteers in a randomized, double-blind, crossover design. Measurements included plasma levels of insulin, catecholamines, free fatty acids (FFAs), and hemodynamic parameters. Insulin sensitivity was calculated as whole-body glucose uptake corrected for the insulin concentration. In a second study, the adenosine reuptake inhibitor dipyridamole was tested using an identical protocol in 10 healthy subjects. RESULTS:Caffeine decreased insulin sensitivity by 15% (P < 0.05 vs. placebo). After caffeine administration, plasma FFAs increased (P < 0.05) and remained higher than during placebo. Plasma epinephrine increased fivefold (P < 0.0005), and smaller increases were recorded in plasma norepinephrine (P < 0.02) and blood pressure (P < 0.001). Dipyridamole did not alter insulin sensitivity and only increased plasma norepinephrine (P < 0.01). CONCLUSIONS:Caffeine can decrease insulin sensitivity in healthy humans, possibly as a result of elevated plasma epinephrine levels. Because dipyridamole did not affect glucose uptake, peripheral adenosine receptor antagonism does not appear to contribute to this effect.
RCT Entities:
OBJECTIVE:Caffeine is a central stimulant that increases the release of catecholamines. As a component of popular beverages, caffeine is widely used around the world. Its pharmacological effects are predominantly due to adenosine receptor antagonism and include release of catecholamines. We hypothesized that caffeine reduces insulin sensitivity, either due to catecholamines and/or as a result of blocking adenosine-mediated stimulation of peripheral glucose uptake. RESEARCH DESIGN AND METHODS: Hyperinsulinemic-euglycemic glucose clamps were used to assess insulin sensitivity. Caffeine or placebo was administered intravenously to 12 healthy volunteers in a randomized, double-blind, crossover design. Measurements included plasma levels of insulin, catecholamines, free fatty acids (FFAs), and hemodynamic parameters. Insulin sensitivity was calculated as whole-body glucose uptake corrected for the insulin concentration. In a second study, the adenosine reuptake inhibitor dipyridamole was tested using an identical protocol in 10 healthy subjects. RESULTS:Caffeine decreased insulin sensitivity by 15% (P < 0.05 vs. placebo). After caffeine administration, plasma FFAs increased (P < 0.05) and remained higher than during placebo. Plasma epinephrine increased fivefold (P < 0.0005), and smaller increases were recorded in plasma norepinephrine (P < 0.02) and blood pressure (P < 0.001). Dipyridamole did not alter insulin sensitivity and only increased plasma norepinephrine (P < 0.01). CONCLUSIONS:Caffeine can decrease insulin sensitivity in healthy humans, possibly as a result of elevated plasma epinephrine levels. Because dipyridamole did not affect glucose uptake, peripheral adenosine receptor antagonism does not appear to contribute to this effect.
Authors: Xuehong Zhang; Demetrius Albanes; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Andrew Flood; Jo L Freudenheim; Edward L Giovannucci; R Alexandra Goldbohm; Karen Jaceldo-Siegl; Eric J Jacobs; Vittorio Krogh; Susanna C Larsson; James R Marshall; Marjorie L McCullough; Anthony B Miller; Kim Robien; Thomas E Rohan; Arthur Schatzkin; Sabina Sieri; Donna Spiegelman; Jarmo Virtamo; Alicja Wolk; Walter C Willett; Shumin M Zhang; Stephanie A Smith-Warner Journal: J Natl Cancer Inst Date: 2010-05-07 Impact factor: 13.506
Authors: Rainer Schneider; Mauritz Grüner; Alexandra Heiland; Martina Keller; Zuzana Kujanová; Martin Peper; Maximilian Riegl; Stefan Schmidt; Petra Volz; Harald Walach Journal: Int J Behav Med Date: 2006
Authors: S van Dieren; C S P M Uiterwaal; Y T van der Schouw; D L van der A; J M A Boer; A Spijkerman; D E Grobbee; J W J Beulens Journal: Diabetologia Date: 2009-09-01 Impact factor: 10.122
Authors: Brendan J Guercio; Kaori Sato; Donna Niedzwiecki; Xing Ye; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Frank B Hu; Shuji Ogino; Kana Wu; Walter C Willett; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544